Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears

NCT ID: NCT06817616

Last Updated: 2025-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-17

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety Analysis of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients Undergoing Rotator Cuff Repair for Massive or Large Rotator Cuff Tears

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rotator Cuff Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with Full-Thickness Rotator Cuff Tears, Including Massive and Large Tears

Group Type EXPERIMENTAL

Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell

Intervention Type BIOLOGICAL

Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell

1. Injection dosage and volume of the study drugs:

* Low dose: 2.5X10 cells/0.5mL
2. Number of injections: Only once during the study period
3. Device: Ultrasound
4. Injection technique: Injection into the lesion by investigator

Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell

1. Injection dosage and volume of the study drugs:

\- High dose: 5X10 cells/1mL
2. Number of injections: Only once during the study period
3. Device: Ultrasound
4. Injection technique: Injection into the lesion by investigator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell

Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell

1. Injection dosage and volume of the study drugs:

* Low dose: 2.5X10 cells/0.5mL
2. Number of injections: Only once during the study period
3. Device: Ultrasound
4. Injection technique: Injection into the lesion by investigator

Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell

1. Injection dosage and volume of the study drugs:

\- High dose: 5X10 cells/1mL
2. Number of injections: Only once during the study period
3. Device: Ultrasound
4. Injection technique: Injection into the lesion by investigator

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 19 years of age and older
* Unilateral shoulder pain with a pain score of 4 or higher.
* patients with a symptom duration of at least three months who have not responded to conventional treatments, including analgesics.
* patients diagnosed with massive or extensive full-thickness rotator cuff tears confirmed by computed tomography arthrography or magnetic resonance imaging.

Exclusion Criteria

* patients diagnosed with small or medium full-thickness rotator cuff tears among study participants with full-thickness rotator cuff tears.
* patients who have received subacromial injection therapy in the affected shoulder within the past three months.
* patients who have undergone rotator cuff surgery on the affected shoulder within the past six months.
* patients exhibiting or suspected of having the following radiological findings: malignant tumors, severe glenohumeral osteoarthritis, or bony abnormalities causing subacromial space narrowing.
* patients presenting with symptomatic cervical spine disorders.
* patients experiencing bilateral shoulder pain.
* patients diagnosed with multiple arthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia.
* patients with neurological deficits.
* Pregnant or breastfeeding patients
* patients unwilling to use effective contraception during the study period.
* patients currently infected with HBV, HCV, or HIV, or those with a positive RPR test result.
* patients with severe conditions that may affect the study, including cardiovascular diseases, renal diseases, hepatic diseases, endocrine disorders, or malignancies.
* patients who are unable to comprehend the questionnaires used for study assessments, including the Visual Analog Scale (VAS), or those with communication difficulties due to psychiatric disorders.
* Any other cases deemed inappropriate for study participation by the investigator.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Korea University Anam Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Woong Kyo Jeong

PI

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Korea University Anamh Hospital

Seoul, Korea, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Woong Kyo Jeong

Role: CONTACT

82-10-4047-2878

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

+82-2-870-3246

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KUAH-25-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Amniotic Membrane for Dacryocystorhinostomy
NCT06226181 RECRUITING PHASE1